fashion -WSS

fashion

author：fashion 2025-09-27 11:32:36 - browse：76

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Military medical care influenced by rank and race, new study finds

focus

explore

WSS

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Pancreatic cancer is often deadly, but new discoveries are raising hope

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Overprescribed: High cost isn't America's only drug problem

Addiction experts warn against a second 'war on drugs'

Anxious about a speech? A startup wants you to pop a minty cardiac drug

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Cancer drug shortages should be causing more outrage

Study: Black kids more likely to die after surgery than white kids

In age of alternative facts, a scholarly course on calling out crap

Readers respond to H5N1 and livestock movements, and more

Activists slam private health insurers over coverage restrictions

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

After affirmative action ruling, medical educators look to 'holistic review'

Second House panel advances two

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare Advantage 2025 payments will dip, Biden administration says

entertainment

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Wearables generate powerful data but its not useful to doctors, yet

Arc Institute generative AI designs new CRISPR systems

Drug companies' payments and gifts affect physicians' prescribing

Helping hospitals and community health centers plan for resilience

Bird flu: Don't repeat Covid's 'health versus the economy' framing

leisure time

focus

explore

focus